Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 10/20 | 1.00 |
| ▸ | TARS1 | P26639 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28173973 | 1.00 | LARS1 (1.00) | LARS1TARS1ALDH1A1MITFMAPT | |
| Hydrochloric Acid SCHEMBL28591957 | 0.98 | LARS1 (0.97) | LARS1TARS1ALDH1A1MITFMAPT | |
| Hydrochloric Acid SCHEMBL28591958 | 0.98 | LARS1 (0.97) | LARS1TARS1ALDH1A1MITFMAPT | |
| SCHEMBL18019130 | 0.92 | LARS1 (0.84) | LARS1TARS1CTSLCTSSCTSK | |
| SCHEMBL28717212 | 0.92 | LARS1 (0.84) | LARS1TARS1CTSLCTSSCTSK | |
| SCHEMBL18019129 | 0.89 | LARS1 (1.00) | LARS1TARS1CTSLCTSSCTSK | |
| SCHEMBL19792904 | 0.88 | LARS1 (0.78) | LARS1TARS1CTSSCTSK | |
| SCHEMBL18019125 | 0.85 | LARS1 (0.74) | LARS1ALDH1A1HTT | |
| SCHEMBL23676433 | 0.85 | LARS1 (0.74) | LARS1TARS1CTSSCTSK | |
| SCHEMBL12448217 | 0.84 | LARS1 (0.73) | LARS1TARS1ALDH1A1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| CN-116134015-A | Selective acyclic nucleotide activating factor for CAMP sensor EPAC1 | 得克萨斯州大学系统董事会 | 2023-05-16 | — | — | CN | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | Oxford Drug Design Limited (GB) | 2021-07-27 | — | — | US | disclosed |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2016129983-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | AARS1, GARS1, ASNS | LARS1 72/4885TARS1 82/4885ALDH1A1 2863/4885 |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | AARS1, ASNS, GARS1 | LARS1 77/4885TARS1 103/4885ALDH1A1 2857/4885 |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | LARS1 2380/4885TARS1 2124/4885ALDH1A1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.